Literature DB >> 3533684

Metabolic consequences of prolonged hyperinsulinemia in humans. Evidence for induction of insulin insensitivity.

A G Marangou, K M Weber, R C Boston, P M Aitken, J C Heggie, R L Kirsner, J D Best, F P Alford.   

Abstract

Hyperinsulinemia is frequently associated with a variety of insulin-resistant states and has been implicated causally in the development of insulin resistance. This study examines the metabolic consequences of prolonged hyperinsulinemia in humans. Basally and 1 h after cessation of a 20-h infusion of insulin (0.5 mU X kg-1 X min-1, aimed at elevating plasma insulin levels to approximately 30 mU/L) or normal saline, subjects were assessed for glucose turnover with 3-[3H]glucose; insulin sensitivity, as measured by either the euglycemic glucose-clamp technique or the intravenous glucose tolerance test (IVGTT) minimal model method of Bergman; and monocyte insulin-receptor binding. Hepatic glucose production (Ra) was suppressed by greater than 95% during each euglycemic clamp and during the 20-h insulin infusion. After the insulin infusion, Ra and glucose utilization rate returned to the initial basal level within 1 h, as did insulin levels. At that time, insulin sensitivity was significantly decreased, as measured by the "insulin action" parameter during the 40- to 80-min phase of the clamp (0.049 +/- 0.003 vs. 0.035 +/- 0.007 min-1, P less than .05) and during the 80- to 120-min phase (0.047 +/- 0.005 vs. 0.039 +/- 0.007 min-1, .05 less than P less than .1).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3533684     DOI: 10.2337/diab.35.12.1383

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  24 in total

1.  Human growth hormone fragment (hGH44-91) produces insulin resistance and hyperinsulinemia but is less potent than 22 kDa hGH in the rat.

Authors:  M Hettiarachchi; A Watkinson; K C Leung; Y N Sinha; K K Ho; E W Kraegen
Journal:  Endocrine       Date:  1997-02       Impact factor: 3.633

2.  Defective glucose utilization in patients with functioning beta-cell tumors persists after tumor excision.

Authors:  G S McGee; M M Kulaylat; N N Abumrad
Journal:  Ann Surg       Date:  1987-10       Impact factor: 12.969

3.  Minimal model analysis of insulin sensitivity and glucose-mediated glucose disposal in type 1 (insulin-dependent) diabetic pancreas allograft recipients.

Authors:  K Osei; D A Cottrell; M L Henry; R J Tesi; R M Ferguson; T M O'Dorisio
Journal:  Diabetologia       Date:  1992-07       Impact factor: 10.122

Review 4.  The chronic cardiovascular risk factor syndrome (syndrome X): mechanisms and implications for atherogenesis.

Authors:  S C Bain; P M Dodson
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

5.  Weight versus pre-insulin-treatment assessment of insulin sensitivity to determine the starting basal insulin dose: a faster way to get to goal?

Authors:  Allen B King; Dawn Clark; Gary S Wolfe
Journal:  J Diabetes Sci Technol       Date:  2013-07-01

6.  Insulin resistance in a case of coexisting insulinoma and type 2 diabetes.

Authors:  G Grunberger
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

7.  The effect of systemic venous drainage of the pancreas on insulin sensitivity in dogs.

Authors:  J Radziuk; P Barron; H Najm; J Davies
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

8.  Insulin action and insulin binding following pancreas transplantation.

Authors:  F Saudek; T Pelikánová; V Bartos; I Reneltová; L Kazdová; J Kovár; L Karasová
Journal:  Diabetologia       Date:  1991-08       Impact factor: 10.122

9.  Effects of chronic systemic insulin delivery on insulin action in dogs.

Authors:  M Homan; C P Nicholson; H Katz; J Perkins; M Haymond; M Jensen; P Butler; R Rizza
Journal:  Diabetologia       Date:  1991-10       Impact factor: 10.122

10.  Increased glucose effectiveness in normoglycemic but insulin-resistant relatives of patients with non-insulin-dependent diabetes mellitus. A novel compensatory mechanism.

Authors:  J E Henriksen; F Alford; A Handberg; A Vaag; G M Ward; A Kalfas; H Beck-Nielsen
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.